Pharma Journalist -

Eisai declared positive results of Phase 3 study for its discovered and developed anticancer agent lenvatinib mesylate in patients grappling with unresectable hepatocellular carcinoma…
Read More...

Merck KGaA, Darmstadt, Germany, and Pfizer assert results from the Phase III JAVELIN Lung 200 trial comparing avelumab to docetaxel in patients with unresectable, recurrent or…
Read More...

Tusker Medical announced the enrollment of first- in-office patients in the OTTER Study implied for Tusker's  TULA (Tubes Under Local Anesthesia) System. Via an approved Investigational…
Read More...

Intralytix proclaimed having sought Food and Drug Administration's clearance to commence Phase I/IIa Clinical Trials at Mount Sinai hospital in New York. Dating back to July,2015,…
Read More...

Regentys, a regenerative medicine company, announced it will partner with Cook Biotech Inc., collaborate to develop a novel treatment for ulcerative colitis.Cook Biotech will develop…
Read More...

Astellas Pharma has acquired Universal Cells. Astellas will gain Universal Cells’ proprietary Universal Donor Cell technology to create cell therapy products that do not require Human…
Read More...

ImmunoQure will collaborate with Servier to advance ImmunoQure's therapeutic human Interferon-α autoantibody through preclinical development and into the clinic where Servier will be…
Read More...

Spineology is exhilarated to declare that enrollment stands complete in the SCOUT clinical trial. The SCOUT (Spineology Clinical Outcomes Trial) IDE, conducted under an FDA-approved…
Read More...

Glooko declared that the US FDA has conceded its Mobile Insulin Dosing System (MIDS) for the titration of long-acting insulin for people with type 2 diabetes. The system includes…
Read More...

Bristol-Myers Squibb Company and Nektar Therapeutics collaborate commercially for Nektar's lead immuno-oncology program, NKTR-214. The companies will jointly develop and…
Read More...